Head and Neck Diseases by Alexandros G.Sfakianakis: Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).

Πέμπτη 30 Μαρτίου 2017

Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).

Related Articles

Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).

Front Oncol. 2017;7:31

Authors: Saba NF

PMID: 28348975 [PubMed - in process]

http://ift.tt/2nCTMt5

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου